Dysentery Plus Conjunctivitis: Shigella Infection Management
Treat empirically for shigellosis with antibiotics immediately—the combination of dysentery and conjunctivitis is highly suggestive of Shigella infection, and prompt antimicrobial therapy reduces severity, duration, and transmission while potentially preventing serious complications and death.
Clinical Recognition
The presentation of dysentery (bloody diarrhea) with conjunctivitis is a classic clinical syndrome strongly indicative of Shigella infection. This combination should trigger immediate empiric treatment without waiting for laboratory confirmation, as Shigella is associated with significant mortality (pooled OR 2.8) while dysentery alone is not 1.
Diagnostic Approach
- Ideally obtain stool microscopy to distinguish Shigella from Entamoeba histolytica (look for trophozoites, not just white cells which are nonspecific) 2
- If microscopy unavailable or no definite trophozoites seen, treat empirically for shigellosis 2
- Important caveat: Amebic dysentery is frequently misdiagnosed—resistant shigellosis is still more likely than amebiasis even after treatment failure 2
First-Line Antibiotic Selection
The choice depends on local resistance patterns, but current evidence supports:
Preferred First-Line Options:
Azithromycin is increasingly recommended as first-line therapy 3, 4:
- Children: Standard pediatric dosing
- Adults: Standard adult dosing
- Particularly appropriate given rising fluoroquinolone resistance
Alternative First-Line (if local susceptibility known):
Ciprofloxacin (fluoroquinolone) 3
Traditional Options (Now Often Resistant):
These should only be used if local susceptibility is confirmed 2:
TMP-SMX (Trimethoprim-Sulfamethoxazole)
- Children: 10 mg/kg/day TMP + 50 mg/kg/day SMX in 2 divided doses × 5 days
- Adults: 160 mg TMP + 800 mg SMX twice daily × 5 days
Ampicillin
- Children: 100 mg/kg/day in 4 divided doses × 5 days
- Adults: 500 mg four times daily × 5 days
Second-Line Options (for resistant strains):
- Nalidixic acid: 55 mg/kg/day in 4 divided doses × 5 days 2
- Tetracycline: 50 mg/kg/day in 4 divided doses × 5 days 2
Treatment Algorithm
- Start empiric antibiotics immediately based on local resistance patterns
- Assess clinical response at 48 hours
- If improving: Complete 5-day course
- If no improvement: Switch to alternative antibiotic 2
- Reassess at 96 hours (4 days total)
- If still no improvement: Refer for stool microscopy to rule out amebiasis 2
- Note: Resistant shigellosis remains more likely than amebiasis at this stage
Critical Pitfalls to Avoid
- Do NOT use mass prophylaxis or treat family contacts routinely—WHO explicitly does not recommend this 2
- Do NOT rely on dysentery alone to identify all Shigella cases requiring treatment—sensitivity ranges from only 1.9-85.9% and is decreasing over time 1
- Do NOT use fluoroquinolones blindly—multiresistant strains are widespread, and resistance can develop rapidly in endemic settings 2, 6
- Do NOT treat for amebiasis unless microscopy shows definite trophozoites OR two different antibiotics for shigellosis have failed 2
Conjunctivitis Management
While the evidence focuses on systemic treatment, the conjunctivitis in Shigella infection typically resolves with appropriate systemic antibiotic therapy for the underlying infection. The conjunctivitis is part of the systemic Shigella syndrome and does not require separate topical treatment beyond supportive care.
Special Considerations
Antibiotic susceptibility testing should be performed periodically by regional reference laboratories given rapid resistance acquisition 2. The landscape of Shigella resistance is dynamic—what works in one region may fail in another, and patterns change over time 5, 6.
Fluoroquinolones (ciprofloxacin, ofloxacin) are highly effective but expensive and carry FDA warnings about serious adverse effects. They are not approved for children or pregnant/lactating women with shigellosis 2.